"Biphenyl Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Whitish aromatic crystalline organic compounds made up of two conjoined BENZENE rings.
| Descriptor ID |
D001713
|
| MeSH Number(s) |
D02.455.426.559.389.185
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Biphenyl Compounds".
Below are MeSH descriptors whose meaning is more specific than "Biphenyl Compounds".
This graph shows the total number of publications written about "Biphenyl Compounds" by people in this website by year, and whether "Biphenyl Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 3 | 1 | 4 |
| 2017 | 5 | 33 | 38 |
| 2018 | 8 | 28 | 36 |
| 2019 | 2 | 15 | 17 |
| 2020 | 1 | 3 | 4 |
| 2021 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Biphenyl Compounds" by people in Profiles.
-
Development of potent and selective Cathepsin C inhibitors free of aortic binding liability by application of a conformational restriction strategy. Bioorg Med Chem Lett. 2021 09 01; 47:128202.
-
Candesartan as a tentative treatment for COVID-19: A prospective non-randomized open-label study. Int J Infect Dis. 2021 Jul; 108:159-166.
-
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat? Clin Sci (Lond). 2021 04 30; 135(8):1009-1014.
-
Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors. Proc Natl Acad Sci U S A. 2021 02 23; 118(8).
-
Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors. Proc Natl Acad Sci U S A. 2021 02 23; 118(8).
-
Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19. Clin Sci (Lond). 2021 02 12; 135(3):465-481.
-
Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Med Hypotheses. 2021 Feb; 147:110486.
-
The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19. Int J Mol Sci. 2020 Nov 15; 21(22).
-
[Impact of the COVID-19 pandemic on the management of heart failure outpatient clinics. Lessons during the lockdown restrictions]. G Ital Cardiol (Rome). 2020 Oct; 21(10):750-756.
-
Complete remission of an advanced basal cell carcinoma after only 3-month treatment with sonidegib: Report of a case and drug management during COVID-19 pandemic. Dermatol Ther. 2020 11; 33(6):e14200.